Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial

Patients had no evidence of cancer following treatment with Jemperli alone, as confirmed by endoscopy, radiology and/or pathology

No disease recurrences reported among responders after median follow-up of more than two years

Data supported recent US approval of Jemperli in this indication

Findings to be presented in a late-breaking oral session at ESMO